Article
|
Open Access
Featured
-
-
Article
| Open Access
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
A phase I open-label trial evaluating the immunogencity, reactogenicity and safety of a peptide-based SARS-CoV-2 vaccine candidate to induce SARS-CoV-2-specific T cell responses.
- Jonas S. Heitmann
- , Tatjana Bilich
- & Juliane S. Walz
-
Article |
Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity
Two malaria vaccines comprising Plasmodium falciparum sporozoites and treatment with either pyrimethamine or chloroquine induced durable protective responses against both the African vaccine strain and a heterologous South American strain of P. falciparum.
- Agnes Mwakingwe-Omari
- , Sara A. Healy
- & Patrick E. Duffy
-
Article |
The National Lung Matrix Trial of personalized therapy in lung cancer
Current outcomes are reported from the ongoing National Lung Matrix Trial, an umbrella trial for the treatment of non-small-cell lung cancer in which patients are triaged according to their tumour genotype and matched with targeted therapeutic agents.
- Gary Middleton
- , Peter Fletcher
- & Lucinda Billingham
-
Letter |
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
Clinical benefit was observed in 34% of a cohort of 215 patients with cancer who received treatment with anticancer drugs outside of their approved label, in the Drug Rediscovery protocol trial.
- D. L. van der Velden
- , L. R. Hoes
- & E. E. Voest
-
Article |
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
Combination therapy with the anti-HIV-1 monoclonal antibodies 3BNC117 and 10-1074 maintains long-term suppression in the absence of antiretroviral therapy in individuals with antibody-sensitive viral reservoirs.
- Pilar Mendoza
- , Henning Gruell
- & Michel C. Nussenzweig
-
Letter |
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
The authors report the first-in-human application of personalized neo-antigen RNA vaccines in patients with melanoma.
- Ugur Sahin
- , Evelyna Derhovanessian
- & Özlem Türeci
-
Letter |
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists
Although imatinib gives good clinical results in chronic myeloid leukaemia (CML), residual disease attributed to quiescent CML stem cells remains in many patients; here glitazones are shown to reduce the pool of CML stem cells and achieve lasting disease eradication in CML patients in combination with imatinib.
- Stéphane Prost
- , Francis Relouzat
- & Philippe Leboulch
-
Outlook |
Nanotechnology: Deliver on a promise
Effective treatment of cancer requires getting the drugs precisely to the target. Enter the nanoparticle.
- Jessica Wright
-
Outlook |
Clinical trials: More trials, fewer tribulations
Clinical studies that group patients according to their molecular profile can make for better and faster drug approval decisions.
- Michael Eisenstein
-
News |
FDA under pressure to relax drug rules
Industry says antibiotic pipeline is being blocked by overly stringent clinical-trial requirements for new treatments.
- Heidi Ledford
-
Comment |
The worm returns
Joel V. Weinstock explains why several clinical trials are deliberately infecting people with helminths to treat autoimmune diseases.
- Joel V. Weinstock
-
News & Views |
Design by trial
A genetic analysis of viruses infecting participants in an HIV vaccine trial indicates that the vaccine is more protective against viruses that have variations at specific sites in the viral envelope. See Letter p.417
- David V. Glidden
-
News |
Drug firm to share raw trial data
Full disclosure could improve health care and restore trust.
- Declan Butler
-
News |
Vaccine trial reveals chinks in HIV's armour
Analysis identifies target for immune response that could improve AIDS vaccines.
- Ewen Callaway
-
News |
Alzheimer’s drugs take a new tack
Hopes pinned on pre-emptive clinical trials after latest setbacks.
- Ewen Callaway
-
Outlook |
Clinical approval: Trials of an anticancer jab
Two vaccines seem to be so effective in preventing HPV infection that mass vaccination has been introduced for girls. But will long-term studies show falls in cervical cancer?
- Julie Clayton
-
News |
India shakes up rules on clinical trials
But compensation scheme draws fire for raising costs for academic researchers.
- Daniel Cressey
-
News |
Stem-cell pioneer banks on future therapies
Japanese researcher plans cache of induced stem cells to supply clinical trials.
- David Cyranoski
-
News |
Europe proposes revision of clinical-trial rules
Much-maligned directive to be overhauled after years of complaints.
- Daniel Cressey
-
Outlook |
Perspective: The right trials
The system for clinical trials must be redesigned if there is to be a decline in breast cancer metastasis, argues Patricia S. Steeg.
- Patricia S. Steeg
-
Outlook |
Perspective: Testing failures
Promising drugs to treat diabetes stumble in the latter stages of clinical testing. Thomas Mandrup-Poulsen explains why — and how to fix it.
- Thomas Mandrup-Poulsen
-
News |
FDA says study overestimated non-compliance with data-reporting laws
US drug regulator finds no evident harm caused by sponsors failing to post drug-trial data.
- Meredith Wadman
-
-
News & Views |
Clinical trials unite mice and humans
Anticancer 'co-clinical' trials, in which mice carrying known mutations are treated in parallel with patients enrolled in a simultaneous clinical study, could help to improve therapeutic outcome. See Letter p.613
- Leisa Johnson
-
News |
Mice guide human drug trial
Parallel approach to cancer study provides genetic insights.
- Heidi Ledford
-
Correspondence |
Informed consent: meet patients' needs
- Silvio Garattini
- , Vittorio Bertele'
- & Rita Banzi
-
Correspondence |
Informed consent: cultural differences
- Gilles Guerrier
- , Didier Sicard
- & Paul T. Brey
-
Editorial |
The darker side of stem cells
An investigation by Nature has found that patients in Texas are receiving unproven stem-cell treatments. The state and the company involved need to ensure that they follow FDA guidelines.
-
Feature |
Biostatistics: Revealing analysis
As the challenges of analysing genomic data evolve, statistical expertise has become more valuable than ever.
- Erika Check Hayden
-
News Feature |
Human experiments: First, do harm
In the 1940s, US doctors deliberately infected thousands of Guatemalans with venereal diseases. The wound is still raw.
- Matthew Walter
-
News |
Informed consent on trial
Lengthy, complicated documents leave many clinical-trial participants in the dark about the risks they face.
- Daniel Cressey
-
News |
Fines expose failings in policing of Indian drug trials
Paltry penalties for doctors involved in unethical clinical trials spark controversial reforms.
- M Sreelata
-
News |
Russian drug law hinders clinical trials
Legislation to increase availability of new medicines has delayed approvals.
- Alla Katsnelson
-
Outlook |
Food: Picky eaters
Clinical trials are testing how careful exposure could protect people with potentially lethal allergies to everyday fare.
- Rebecca Kessler
-
News |
Stem-cell pioneer bows out
Geron halts first-of-its-kind clinical trial for spinal therapy.
- Monya Baker
-
News |
Targeted treatment tested as potential cancer cure
Trial will deploy genetically targeted therapy early, rather than as last resort.
- Erika Check Hayden
-
News |
Depression drug disappoints
Failure of a promising compound casts a shadow on others.
- Heidi Ledford
-
Q&A |
Turning point: Qin Liu
Biostatistician leaves medical career in China for cancer research in the United States.
- Virginia Gewin
-
News |
Malaria vaccine results face scrutiny
Experts question early release of incomplete trial data.
- Declan Butler
-
News |
A fight for life that united a field
Nobel-prizewinner Ralph Steinman tried to beat his cancer with vaccines based on the dendritic cells he discovered.
- Lauren Gravitz
-
News |
Drug shortage slows clinical trials
US researchers faced with cancer-drug shortfall struggle to keep trials on track.
- Heidi Ledford
-
News Feature |
Translational research: 4 ways to fix the clinical trial
Clinical trials are crumbling under modern economic and scientific pressures. Nature looks at ways they might be saved.
- Heidi Ledford
-
News |
Clues emerge to explain first successful HIV vaccine trial
Immune responses of patients could point way forward for future vaccines.
- Ewen Callaway
-
Editorial |
Who watches the watchmen?
Some commercial firms that oversee the ethics and scrutiny of clinical trials have been found wanting. Human volunteers in research deserve better.
-
News Feature |
Experimental therapies for Parkinson's disease: Why fake it?
How 'sham' brain surgery could be killing off valuable therapies for Parkinson's disease.
- Alla Katsnelson
-
News |
Gene-therapy enzymes make unpredicted errors
Techniques show mistakes of 'highly specific' molecular tools.
- Heidi Ledford
-
News |
Vaccine trial's ethics criticized
Collapsed trial fuels unfounded vaccine fears.
- Priya Shetty
-
News |
Therapeutic success stifles medical progress
Drug development loses momentum as patients shun clinical trials for tried and tested treatments. Could payment for participation be the answer?
- Heidi Ledford
-
Clinical trial links oncolytic immunoactivation to survival in glioblastoma
Designing smarter cancer prevention trials